Skip to main content
. 2003 Mar 4;88(5):748–753. doi: 10.1038/sj.bjc.6600793

Figure 3.

Figure 3

Effect of butyrate and UDCA on p38 and p42/44 MAP kinase activity. AA/C1 cells treated with 6 mM butyrate or 10 μM UDCA for 24 h. Cells were examined for the presence of activated, phosphorylated p38 MAP kinase (pP38) and p42/44 MAP kinase (pP42/44) by Western blotting. PD98059 was also included with UDCA treatments (lane 5) to inhibit activation of p42/44 MAP kinase by MEK1, and SB202190 was included with butyrate treatments (lane 3) to inhibit p38 MAP kinase. Equal loading of gels was confirmed using an antibody to total P38 and P42/44 MAP kinase. The blot shown is a representative of three similar experiments performed.